Clinical Trials

582 enrolled

Rectal Neoplasms

NCT05544136 2026-02-27

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

12 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07033819 2026-02-27

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

48 enrolled

Gynecologic

Ovarian Neoplasms

NCT03978663 2026-02-20

TRIO

40 enrolled

Phase 1/2 Not yet recruiting

High-Risk Cancer

NCT07217990 2026-02-17

NoCUT-BC

84 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07407244 2026-02-17

AKRA

268 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

100 enrolled

Phase 4 Active not recruiting

Colonic Neoplasms, Neoplasm, Residual

NCT02875314 2026-02-12

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

250 enrolled

CNS

Medulloblastoma

NCT02212860 2026-02-11

SIGNAL 2

Phase NA Completed

139 enrolled

Tumor-Agnostic

Neoplasms

NCT05412225 2026-02-11

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

Phase 1 Recruiting

60 enrolled

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms

NCT03387553 2026-02-09

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

31 enrolled

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT05333874 2026-02-09

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06386887 2026-02-09

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Phase NA Recruiting

20 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Intermittent Fasting

NCT06417190 2026-02-04

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

20 enrolled

Tumor-Agnostic

Neoplasms

NCT06739655 2026-02-04

PRADAIIBE

Phase NA Recruiting

180 enrolled

Breast Neoplasms, Neoplasms

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

111 enrolled

Breast Neoplasms

NCT07385001 2026-02-03

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Phase 1/2 Recruiting

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

550 enrolled

Rectal Neoplasms

NCT07370337 2026-01-27

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

50 enrolled

Squamous Cell Carcinoma of External Auditory Canal

NCT06660810 2026-01-15

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

2 enrolled

Sarcoma

NCT07103395 2026-01-14

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

56 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498154 2025-12-19

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

200 enrolled

Breast Neoplasms

NCT07038122 2025-12-18

RESET

874 enrolled

Locally Advanced Rectal Carcinoma

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

35 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05659251 2025-12-02

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT05882513 2025-12-02

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07244978 2025-12-02

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

49 enrolled

Esophageal Squamous Cell Carcinoma

NCT07259122 2025-12-02

ZBR in WM

43 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT07254858 2025-11-28

CISN-L

302 enrolled

Breast Neoplasms

NCT03926338 2025-11-20

PICC

270 enrolled

Turcot syndrome, Colorectal Neoplasms

NCT07236320 2025-11-19

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Phase NA Completed

200 enrolled

Esophageal Squamous Cell Carcinoma

NCT07202819 2025-10-02

"NAC-MRI"

Phase NA Recruiting

76 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT04727307 2025-09-30

AB-LATE02

202 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT06831136 2025-09-10

PANCARDINAL-2

Phase 2/3 Active not recruiting

24 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

178 enrolled

Cholangiocarcinoma

NCT07081360 2025-08-29

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

262 enrolled

Pancreatic Neoplasms

NCT07142863 2025-08-27

Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients

23 enrolled

Sarcoma

Osteosarcoma

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

30 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07134218 2025-08-21

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

180 enrolled

Rectal Neoplasms

NCT06664411 2025-08-19

Pola-ZR2P in Previously Untreated DLBCL

80 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06611813 2025-08-12

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

30 enrolled

Breast Neoplasms

NCT06874933 2025-08-12

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

35 enrolled

Breast Neoplasms

NCT06876636 2025-07-29

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

99 enrolled

Breast Cancer Metastatic

NCT07089199 2025-07-28

TitAN

34 enrolled

NSCLC

NCT06734702 2025-07-24

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

497 enrolled

Neoadjuvant Therapy

NCT04268121 2025-07-23

NEONEC

EndocrineGastrointestinal

78 enrolled

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT00354393 2025-07-15

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Phase 2 Completed

9 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

27 enrolled